US regulators have expanded the scope of Novartis’ Promacta to include earlier use of the drug to treat adults and paediatric patients with severe aplastic anaemia (SAA) in combination with standard immunosuppressive therapy (IST).
The annual PharmaTimes Marketer of the Year and Communications Team of the Year awards ceremonies took place last night at the Tower Hotel London, with a special addition for this year – the PharmaTimes Sales Awards.
UK drug discovery and development group Mission Therapeutics has signed a deal with AbbVie focusing on early stage development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease.
Cost regulators for the NHS in England and Wales have now published final guidelines recommending Mylotarg, alongside daunorubicin and cytarabine, as an option for untreated de novo CD33-positive acute myeloid leukaemia (AML).
The National Institute for Health Research is streaming £5 million of global health funding into research looking at how infectious diseases spread and develop into epidemics in low- and middle-income countries.